US pharma major Bristol-Myers Squibb and BioLabs, a network of shared lab facilities for high-potential life-science start-ups, located in the nation’s key biotech innovation clusters, today announced Bristol-Myers Squibb as the Founding Sponsor of BioLabs’ newest location, BioLabs@NYULangone. 1 November 2017
Australian trade federation AusBiotech gathered for its annual meeting last week to network, collaborate and discuss sector successes and issues. 31 October 2017
The European Medicines Agency (EMA) has validated Bristol-Myers Squibb’s type II variation application to expand the current indications for Opdivo (nivolumab) to include the treatment of patients with melanoma who are at high risk of disease recurrence following complete surgical resection. 30 October 2017
UK-based rare and specialty diseases specialist Mereo BioPharma has reached an agreement with Anglo-Swedish pharma major AstraZeneca for an exclusive license, including an option to acquire, AZD9668, an oral inhibitor of neutrophil elastase. 30 October 2017
The US Food and Drug Administration has accepted Bayer's Biologics License Application (BLA) filing for BAY94-9027 (damoctocog alfa pegol), an extended half-life site-specifically PEGylated recombinant human Factor VIII compound, for the treatment of hemophilia A in adults and adolescents 12 years of age and over. 30 October 2017
The Prix Galien USA Committee on Thursday honored excellence in the biopharmaceutical and medical industry for research, development and innovation at its 11th annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City. 27 October 2017
Roche has claimed that new data presented at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Paris on Ocrevus (ocrelizumab) advances clinical understanding of underlying progression in multiple sclerosis (MS). 27 October 2017
East Coast-based Regeneron has announced it will invest $100 million in its manufacturing site in Ireland, adding 300 new jobs, to boost drug substance production capacity. 26 October 2017
The results of the Phase III ARROW trial show that US biotech Amgen’s Kyprolis (carfilzomib) with dexamethasone is more effective in relapsed and refractory multiple myeloma at the once-weekly 70 mg/m2 dose than it is when administered at the 27 mg/m2 dose with dexamethasone. 24 October 2017
Telix Pharmaceuticals, an Australian biopharma developing diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), has launched its initial public offering (IPO) to raise A$50 million ($39 million). 24 October 2017
Vascular Biogenics, a cancer-focused biopharma operating under the name of VBL Therapeutics, has announced the opening of its new gene therapy manufacturing plant in Modiin, Israel. 24 October 2017
ADC Therapeutics, an oncology drug development company focused on antibody drug conjugates (ADCs) targeting major cancers, has raised $200 million through a private placement. 23 October 2017
Japan’s Astellas Pharma and Washington, USA-based Universal Cells have agreed terms for a co-development and commercialization project based on the latter’s Universal Donor Cell technology. 20 October 2017
DCPrime, a clinical-stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma, a German contract manufacturing organization in gene and cell therapies, have entered into a strategic manufacturing agreement. 19 October 2017
London-listed biotech services firm Abzena and Germany’s UGA Biopharma have announced the completion of a biosimilar cell line to treat multiple sclerosis (MS). 19 October 2017
US drugmaker AbbVie has announced an immuno-oncology (I-O) research collaboration with Harpoon Therapeutics, a Californian biotech developing novel T-cell recruiting biologic therapies. 18 October 2017
Antony Odell is resigning from his role as chief executive of UK-based regenerative medicine company Tissue Regenix with immediate effect, the company has announced. 18 October 2017
Viennese immunotherapy specialist Hookipa Biotech has appointed a new chairman, Dr Jan van de Winkel, the current president and chief executive of Genmab. 18 October 2017
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024